NCT05656131 2026-03-17
Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer
Sun Yat-sen University
Phase 2 Suspended
Clinical Trials
10 trialsNCT07382713 2026-02-03
Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer
The First Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
NCT07353437 2026-01-20
Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco)
Fudan University
Phase 2 Not yet recruiting
NCT05938374 2025-12-11
SPARE-03
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT05582499 2025-08-22
FASCINATE-N
Fudan University
Phase 2 Recruiting
NCT07047066 2025-07-02
A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma
Tongji Hospital
Phase 2 Not yet recruiting
NCT04102124 2025-06-24
A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Terminated
NCT06827717 2025-05-31
Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma
Sun Yat-sen University
Phase 2 Recruiting
NCT06971211 2025-05-14
PARTOM
First Hospital of China Medical University
Phase 2 Recruiting
NCT05894018 2025-05-13
RAFAS-001
Sun Yat-sen University
Phase 2 Recruiting